Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,044JPY
29 Jul 2016
Change (% chg)

¥-9 (-0.15%)
Prev Close
¥6,053
Open
¥5,953
Day's High
¥6,114
Day's Low
¥5,898
Volume
1,267,100
Avg. Vol
988,115
52-wk High
¥8,800
52-wk Low
¥5,366

Latest Key Developments (Source: Significant Developments)

Eisai to sell subsidiary to Sekisui Chemical
Friday, 20 Nov 2015 01:30am EST 

Eisai Co Ltd:To sell 17,979,195 shares (100 pct stake) in its wholly owned Tokyo-based subsidiary EIDIA Co.,Ltd to Sekisui Chemical Co Ltd, at price of 22,450 mln yen in total, on Dec. 28.To cut stake in the subsidiary to 0 pct from 100 pct.  Full Article

Eisai announces business integration with subsidiary of Ajinomoto
Thursday, 15 Oct 2015 02:00am EDT 

Eisai Co Ltd:To tranfer gastroenterology diseases related business to a wholly owned subsidiary of Ajinomoto, effective April 1, 2016.Subsidiary of Ajinomoto to issue 6,000 shares to the company.The subsidiary of Ajinomoto to change name to EA Pharma Co Ltd.To hold 60 pct stake in EA Pharma.  Full Article

Eisai amends consolidated mid-year outlook for FY 2016
Tuesday, 29 Sep 2015 07:30pm EDT 

Eisai Co Ltd:Says the company lowered the consolidated mid-year outlook for revenue to 275,000 mln yen from 277,500 mln yen for the fiscal year ending March 31, 2016.Operating profit forecast increased to 14,500 mln yen from 10,000 mln yen.Ordinary profit forecast increased to 14,000 mln yen from 8,400 mln yen.Net profit forecast increased to 9,000 mln yen from 6,000 mln yen.Earnings per share increased to 30.98 yen from 20.66 yen.Says profit outlook raised due to the cost reduction.  Full Article

Eisai Co Ltd announces FDA acceptance of NDA
Monday, 14 Sep 2015 08:30am EDT 

Eisai Co Ltd:Announces FDA acceptance of NDA for review of fycompa oral suspension for adjunctive therapy in the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy age 12 and older.  Full Article

Eisai Co Ltd and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant
Monday, 31 Aug 2015 07:30am EDT 

Eisai Co Ltd:Says Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement.Says that they have entered into a worldwide collaboration agreement for the development and commercialization of Eisai's clinical candidate lemborexant, a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia.  Full Article

JCR Pharmaceuticals announces feasibility testing contract with Eisai
Tuesday, 21 Jul 2015 02:00am EDT 

JCR Pharmaceuticals Co Ltd:Says JCR Pharmaceuticals signed a feasibility testing contract with Eisai Co Ltd on July 21, regarding on discovering therapeutic medication through J-Brain Cargo, a technology owned by JCR Pharmaceuticals.  Full Article

Eisai to sell U.S.-based factory to Biogen
Thursday, 16 Jul 2015 09:15am EDT 

Eisai Co Ltd:To sell North Carolina-based factory owned by its U.S.-based subsidiary to a U.S.-based company Biogen Inc. within the second quarter of fiscal year ending March 2016.  Full Article

R&I downgrades Eisai Co Ltd's rating to "A+" and announces stable outlook
Monday, 6 Jul 2015 02:00am EDT 

Eisai Co Ltd:Rating and Investment Information, Inc. (R&I) downgraded Eisai's rating to "A+", previously "AA-".Rating outlook is stable.  Full Article

Eisai Co Ltd Announces FDA Approval of FYCOMPA
Monday, 22 Jun 2015 08:04am EDT 

Eisai Co Ltd:Says Announces FDA approval of fycompa (perampanel) ciii for adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy age 12 and older.Says U.S. FDA approved fycompa ciii for adjunctive therapy in treatment of primary generalized tonic-clonic seizures.  Full Article

Eisai Co Ltd and Genomics plc to collaborate in analyses of large-scale genotype/phenotype data to inform drug development
Sunday, 12 Apr 2015 07:01pm EDT 

Eisai Co Ltd and Genomics plc:Announce collaborative agreement to use Genomics' sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning.Genomics plc, Oxford based genome analytics company, will be partnering with Eisai's new Integrated Human Genomics (IHGx) Research Unit, which operates directly under the supervision of Eisai Product Creation Systems' chief clinical officer.  Full Article

BRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial

* Eisai and Halozyme initiate Phase 1b/2 clinical trial with first patient dosing of eribulin in combination with PEGPH20 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)